Stay updated on Bempegaldesleukin Combo in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Bempegaldesleukin Combo in Urothelial Cancer Clinical Trial page.

Latest updates to the Bempegaldesleukin Combo in Urothelial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for the bempegaldesleukin plus nivolumab study is now displayed, including its completed status, participation criteria, study design and outcomes, participating locations, and study documents.SummaryDifference86%

- Check17 days agoChange DetectedThe study record remains inaccessible behind a 403 Forbidden page. The footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces NIH website updates and says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check31 days agoChange DetectedThe revision number in the footer changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the trial details, with added HTML indicating a 403 state. This means the NCT03785925 record is currently inaccessible on ClinicalTrials.gov.SummaryDifference18%

Stay in the know with updates to Bempegaldesleukin Combo in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bempegaldesleukin Combo in Urothelial Cancer Clinical Trial page.